Suppr超能文献

针对肾素-血管紧张素系统成分的疫苗。

Vaccines against components of the renin-angiotensin system.

机构信息

Tecnologico de Monterrey, Escuela de Medicina y Ciencias de la Salud, Medicina Cardiovascular y Metabolómica, Tecnologico de Monterrey, Monterrey, NL, Mexico.

Advanced Center for Chronic Diseases (ACCDiS), Facultad de Ciencias Químicas y Farmacéuticas y Facultad de Medicina, Universidad de Chile, Santiago, Chile.

出版信息

Heart Fail Rev. 2021 May;26(3):711-726. doi: 10.1007/s10741-020-10033-1. Epub 2020 Sep 29.

Abstract

Even though effective drugs for treating hypertension are available, a great percentage of patients have inadequate control of their blood pressure. Unwanted side effects and inappropriate oral drug adherence are important factors that contribute to the global problem of uncontrolled hypertension. Vaccination could provide a revolutionary therapy with long-lasting effects, increasing patient compliance and therefore better control of high blood pressure. Nowadays, current immunization approaches against hypertension target renin, angiotensin I, angiotensin II, and angiotensin II type 1 receptor, key elements of the renin-angiotensin system. This article reviews the different vaccination attempts with proteins and peptides against the different molecules of the renin-angiotensin system in the last two decades, safety issues, and other novel prospects biomarkers in hypertension, and summarizes the potential of this immunomodulatory approach in clinical practice.

摘要

尽管有有效的降压药物可用,但仍有很大一部分患者的血压控制不理想。不良的副作用和不适当的口服药物依从性是导致全球高血压控制不佳的重要因素。疫苗接种可以提供一种具有持久效果的革命性治疗方法,提高患者的依从性,从而更好地控制高血压。目前,针对高血压的免疫接种方法主要针对肾素、血管紧张素 I、血管紧张素 II 和血管紧张素 II 型 1 受体,这些都是肾素-血管紧张素系统的关键元素。本文综述了过去 20 年中针对肾素-血管紧张素系统不同分子的蛋白和肽的不同疫苗接种尝试、安全性问题以及高血压的其他新型生物标志物前景,并总结了这种免疫调节方法在临床实践中的潜力。

https://cdn.ncbi.nlm.nih.gov/pmc/blobs/0de2/7524378/20b16645c0c5/10741_2020_10033_Fig1_HTML.jpg

文献AI研究员

20分钟写一篇综述,助力文献阅读效率提升50倍。

立即体验

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

马上搜索

文档翻译

学术文献翻译模型,支持多种主流文档格式。

立即体验